First detection of a Mycobacterium tuberculosis XDR clinical isolate harbouring an RpoB I491F mutation in a Ukrainian patient treated in Germany, October 2023

Author:

Friesen Inna1ORCID,Dreyer Viola23ORCID,Klingmüller Angela4,Zuber Sylvia4ORCID,Hoffmann Ada M5ORCID,Suárez Isabelle4ORCID,Schütz Beatrice6,Preßel Tim7,Andres Sönke1,Niemann Stefan823,Rybniker Jan89410ORCID

Affiliation:

1. Research Center Borstel, Leibniz Lung Center, Supranational and National Reference Center for Mycobacteria, Borstel, Germany

2. German Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, Borstel, Germany

3. Research Center Borstel, Leibniz Lung Center, Molecular and Experimental Mycobacteriology, Borstel, Germany

4. Department I of Internal Medicine, Division of Infectious Diseases, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany

5. Institute for Medical Microbiology, Immunology and Hygiene, University of Cologne, Medical Faculty and University Hospital of Cologne, Cologne, Germany

6. Klinikum Dorsten, St. Elisabeth-Krankenhaus, Dorsten, Germany

7. Eurofins MVZ Medizinisches Labor Gelsenkirchen GmbH, Eurofins GeLaMed, Gelsenkirchen, Germany

8. These authors contributed equally to this work and share last authorship.

9. German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany

10. Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany

Abstract

This report documents the case of a Ukrainian patient infected with an extensively drug-resistant (XDR) lineage 2 Mycobacterium tuberculosis strain harbouring the rifampicin resistance mutation RpoB I491F. This mutation is not detected by routine molecular WHO-recommended rapid diagnostics, complicating the detection and treatment of these strains. The occurrence of such mutations underscores the need for enhanced diagnostic techniques and tailored treatment regimens, especially in eastern Europe where lineage 2 strains and XDR-tuberculosis are prevalent.

Publisher

European Centre for Disease Control and Prevention (ECDC)

Reference13 articles.

1. World Health Orgznization (WHO). Global tuberculosis report 2023. Geneva: WHO; 2023. Available from: https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2023

2. World Health Organization (WHO). WHO operational handbook on tuberculosis: module 3: diagnosis: rapid diagnostics for tuberculosis detection: web annex B: critical concentrations for pretomanid and cycloserine: WHO policy statement. 3rd ed. Geneva: WHO; 2024. Available from: https://iris.who.int/handle/10665/376285

3. Assessing pretomanid for tuberculosis (APT), a randomized phase 2 trial of pretomanid-containing regimens for drug-sensitive tuberculosis: 12-week results.;Dooley;Am J Respir Crit Care Med,2023

4. Pretomanid pharmacokinetics in the presence of rifamycins: interim results from a randomized trial among patients with tuberculosis.;Ignatius;Antimicrob Agents Chemother,2021

5. Tuberculosis variant with rifampin resistance undetectable by Xpert MTB/RIF, Botswana.;Modongo;Emerg Infect Dis,2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3